Category: News
-
FDA Approves a New Sunscreen Ingredient for the First Time in 20 Years: What It Means for You
For the first time in two decades, Americans are finally getting access to a new sunscreen active ingredient. On June 9, 2026, the U.S. Food and Drug Administration (FDA) officially approved bemotrizinol as a permitted sunscreen filter, marking a major shift in how well U.S. sunscreens can protect against the sun’s most harmful rays. If…
-
FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug‑Induced Liver Injury
The U.S. Food and Drug Administration has taken an important step toward modernizing how new medicines are evaluated before they ever reach human testing. In early June 2026, the agency announced that it accepted the first Letter of Intent for an in silico, or computer‑based, drug development tool designed to help predict drug‑induced liver injury.…
-
AD109 and the SynAIRgy Phase 3 Trial: What a Once Daily Pill Could Mean for Treating Obstructive Sleep Apnea
Obstructive sleep apnea, or OSA, affects millions of adults and often goes untreated because the most common therapy – the CPAP machine – can be uncomfortable or difficult to use every night. Many people simply cannot tolerate the mask, the noise, or the feeling of forced air. For years, researchers have been searching for an…
-
The American Cancer Society Now Recommends Blood Tests As A New Option For Colorectal Cancer Screening
Colorectal cancer has long been one of the most preventable yet deadly cancers in the United States. For years, doctors have emphasized the importance of screening because catching this cancer early can dramatically improve survival. Now, the American Cancer Society (ACS) has updated its guidelines to include a new tool in the fight against colorectal…
-
Picloram Weed killer linked to early-onset colon cancer
Colon cancer has long been considered a disease of older age. For decades, most cases were diagnosed in people over 50, and screening guidelines were built around that assumption. But over the past 20 years, something unsettling has been happening. Colon and rectal cancer rates have been climbing steadily among younger adults, including people in…
-
Long‑Term Chlorpyrifos Exposure Raises Parkinson’s Risk – What Residents Near Farms Should Know
Researchers found that people who lived or worked near sustained chlorpyrifos use had over 2.5 times the risk of developing Parkinson’s disease compared with those with little or no exposure. Lab work in mice and zebrafish also showed movement problems, loss of dopamine neurons, brain inflammation, and buildup of alpha‑synuclein – the same hallmarks seen…
-
A New Path to Stopping Epstein‑Barr Virus: How Scientists Created Human Antibodies That Block Infection
Epstein‑Barr virus (EBV) is one of the most common viruses on Earth, yet it rarely makes headlines. Most people catch it at some point in their lives, often without knowing it. But beneath its quiet reputation, EBV is linked to a surprising number of serious health problems – from infectious mononucleosis (“mono”) to certain cancers…
-
Why Estrogen Patches Are Suddenly Hard to Find – And What Women Can Do About It
For many women navigating perimenopause or menopause, estrogen patches have become a lifeline. They’re small, discreet, and deliver a steady dose of hormone therapy that can ease hot flashes, night sweats, brain fog, and the general feeling that your body has suddenly changed the rules without warning. But over the past several months, women across…
-
Common Food Preservatives Linked to Diabetes and Cancer
Food preservatives are everywhere. They help keep packaged foods fresh, prevent mold and bacteria, and extend shelf life. Without them, many grocery store staples wouldn’t last long enough to make it from factory to kitchen. But growing research suggests that some commonly used food preservatives may be linked to higher risks of serious health conditions,…
-
FDA Expands Addyi Approval to Treat Postmenopausal Libido – What It Means and What to Know
Low sexual desire after menopause is common, and on December 15, 2025 the FDA expanded the label for Addyi (flibanserin) to include some postmenopausal women. This is a notable change: Addyi was first approved in 2015 for certain premenopausal women, and the new decision gives doctors another FDA‑cleared option for women under 65 who meet…